Answers are grounded in this paper and cite their sources.
Identifies PLK-1 inhibitors in Centella asiatica, suggesting potential for cancer treatment.
Polo-like kinase-1 (PLK-1) is a crucial enzyme to regulate the cell division and cell cycle, making therapeutic target for cancer treatment. The present study aims to identify potential PLK-1 inhibitors from the Centella asiatica (C. asiatica) using UHPLC and in-silico approaches. The 90% ethanol-aqueous extract of C. asiatica whole plant, which was prepared at room temperature, contained ten bioactive compounds including rutin, quercetin, kaempferol, chlorogenic acid, fisetin, apigenin, asiatic acid, fumaric acid, betulinic acid and ursolic acid identified by UHPLC method. All the identified compounds (ligands) were computed against the PLK-1 (PDB ID: 4A4L) for their molecular docking as well as molecular dynamic (MD) simulation studies through Schrödinger 2021-2022, NY, USA software. As our findings, rutin was identified as a promising PLK-1 inhibitor that exhibited significant docking score -13.07 and high stability within the binding pockets of PLK-1 protein as compared to control drug onvansertib. Furthermore, experimental validation is urgently needed for future translational research to develop rutin as potent PLK-1 inhibitor for treating cancer.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: